News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

High compliance with Optune linked to greatest survival benefit for glioblastoma

Al's Comment:

 There is a dose response curve. (Which also should convince the naysayers that the device is effective)   The better the compliance, the better the patients do. They have been saying 75% is the target compliance rate but the new data shows that 90% should be the target.  Those patients who had a compliance rate of 90% or more, had a survival rate of 29.3% at 5 years, compared to the control group (temodar) which had a 4.5% survival rate, an almost 650% increase in survival rate.
   With a compliance of 70-80%, the 5 year survival rate drops to 19.9%.   Still much better than the control group... so don't stress too much if you can't hit the 90%, but try.


Posted on: 11/21/2017

High compliance with Optune linked to greatest survival benefit for glioblastoma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc